Biopharmaceutical firm SuppreMol has raised €16m ($20.6m) in series D funding in a round backed by MIG AG, Santo Holding and BioMedPartners AG as co-lead investors. Also joining the round were FCP Biotech Holding and research group the Max Planck Society. The round was made up out of two closes with the same investors. The…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
